<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.infectagentscancer.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Infectious Agents and Cancer - Latest Articles</title>
        <link>http://www.infectagentscancer.com</link>
        <description>The latest research articles published by Infectious Agents and Cancer</description>
        <dc:date>2012-01-30T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/2" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/1" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/25" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/24" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/23" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/22" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/21" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/20" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/19" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/6/1/18" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/2">
        <title>Hepatitis C virus to hepatocellular carcinoma</title>
        <description>Hepatitis C virus causes acute and chronic hepatitis and can lead to permanent liver damage and hepatocellular carcinoma  (HCC) in a significant number of patients via oxidative stress, insulin resistance (IR), fibrosis, liver cirrhosis and HCV induced steatosis. HCV induced steatosis and oxidative stress causes steato-hepatitis and these pathways lead to liver injury or HCC in chronic HCV infection. Steatosis and oxidative stress crosstalk play an important role in liver damage in HCV infection. This Review illustrates viral and host factors which induce Oxidative stress, steatosis and leads toward HCC. It also expresses Molecular cascade which leads oxidative stress and steatosis to HCC.</description>
        <link>http://www.infectagentscancer.com/content/7/1/2</link>
                <dc:creator>Shah Jahan</dc:creator>
                <dc:creator>Usman Ashfaq</dc:creator>
                <dc:creator>Muhammad Qasim</dc:creator>
                <dc:creator>Saba Khaliq</dc:creator>
                <dc:creator>Muhammad Javed Saleem</dc:creator>
                <dc:creator>Nadeem Afzal</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:2</dc:source>
        <dc:date>2012-01-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-2</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-2-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-01-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/1">
        <title>mTOR Inhibitors: A Novel Class of Anti Cancer Agents</title>
        <description>N/A</description>
        <link>http://www.infectagentscancer.com/content/7/1/1</link>
                <dc:creator>Haris Riaz</dc:creator>
                <dc:creator>Talha Riaz</dc:creator>
                <dc:creator>Syed Hussain</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:1</dc:source>
        <dc:date>2012-01-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-1</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-1-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/25">
        <title>A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago</title>
        <description>Background:
We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings.
Methods:
In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later.
Results:
Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and &#8805; 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (&#8805; 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69).
Conclusions:
Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.</description>
        <link>http://www.infectagentscancer.com/content/6/1/25</link>
                <dc:creator>Alicia McDonald</dc:creator>
                <dc:creator>Frank Jenkins</dc:creator>
                <dc:creator>Clareannn Bunker</dc:creator>
                <dc:creator>John Wilson</dc:creator>
                <dc:creator>Alan Patrick</dc:creator>
                <dc:creator>Joel Weissfeld</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:25</dc:source>
        <dc:date>2011-12-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-25</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-25-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>25</prism:startingPage>
        <prism:publicationDate>2011-12-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/24">
        <title>Low Frequency of Human Papillomavirus Infection in Conjunctival Squamous Cell Carcinoma of Mexican Patients</title>
        <description>Background:
The relationship between Human Papillomavirus (HPV) infection and conjunctiva cancer is controversial. HPV detection will provide more information about the role of this infectious agent in the biology of conjunctiva cancer. In the present study, DNA extracted and purified from 36 Conjunctival Squamous Cell Carcinomas (CSCC) was evaluated by PCR for HPV DNA sequences. The results were correlated with the clinical and histopathological variables.
Results:
The results showed that HPV DNA was present in 8 CSCC samples (22%); HPV16 was the sole type detected. Significant association was found between HPV detection and the limbus tumor subtype (p = 0.03). All the samples were non-metastatic squamous cell carcinoma.
Conclusions:
The HPV presence in CSCC from Mexican patients is not a common event.</description>
        <link>http://www.infectagentscancer.com/content/6/1/24</link>
                <dc:creator>Raul Peralta</dc:creator>
                <dc:creator>Alejandra Valdivia</dc:creator>
                <dc:creator>Perla Estanol</dc:creator>
                <dc:creator>Vanessa Villegas</dc:creator>
                <dc:creator>Carolina Pimienta</dc:creator>
                <dc:creator>Eugenio Trevino</dc:creator>
                <dc:creator>Daniel Marrero</dc:creator>
                <dc:creator>Monica Mendoza</dc:creator>
                <dc:creator>Florinda Jimenez</dc:creator>
                <dc:creator>Leonardo Villalvazo</dc:creator>
                <dc:creator>Miriam Tejeda</dc:creator>
                <dc:creator>Mauricio Salcedo</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:24</dc:source>
        <dc:date>2011-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-24</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-24-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>24</prism:startingPage>
        <prism:publicationDate>2011-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/23">
        <title>Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array.</title>
        <description>Background:
Certain Human Papillomaviruses (HPVs) are the infectious agents involved in cervical cancer development. Detection of HPVs DNA is part of the cervical cancer screening protocols and HPVs genotyping has been proposed for its inclusion in these preventive programs. The aim of this study was to evaluate three novel genotyping tests, namely Qiagen LQ, RH and PS, in clinical samples with and without abnormalities. For this, 305 cervical samples were processed and the results of the evaluated techniques were compared with those obtained in the HPVs diagnostic process in our lab, by using HC2 and Linear Array (LA) technologies.
Results:
The concordances and kappa statistics (k) for each technique compared with HC2 were 98.69% (k = 0.94) for LQ, 98.03% (k = 0.91) for RH and 91.80% (k = 0.82) for PS. There was a very good agreement in HPVs type-specific concordance for the most prevalent types HPV16 (kappa range = 0.83-0.90), HPV18 (k.r.= 0.74-0.80) and HPV45 (k.r.= 0.82-0.90).
Conclusions:
The three tests showed an overall good concordance for HPVs detection when compared with HR-HC2 system. LQ and RH rendered lower detection rate for multiple infections than LA genotyping. However, our understanding of the clinical significance of multiple HPVs infections is still incomplete and therefore the relevance of the lower ability to detect multiple infections needs to be evaluated.</description>
        <link>http://www.infectagentscancer.com/content/6/1/23</link>
                <dc:creator>J Godinez</dc:creator>
                <dc:creator>S Tous</dc:creator>
                <dc:creator>N Baixeras</dc:creator>
                <dc:creator>J Moreno-Crespi</dc:creator>
                <dc:creator>M Alejo</dc:creator>
                <dc:creator>M Lejeune</dc:creator>
                <dc:creator>I Bravo</dc:creator>
                <dc:creator>F Bosch</dc:creator>
                <dc:creator>S de Sanjose</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:23</dc:source>
        <dc:date>2011-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-23</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-23-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>23</prism:startingPage>
        <prism:publicationDate>2011-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/22">
        <title>Prevalence and predictors of Kaposi Sarcoma Herpes Virus seropositivity: A cross-sectional  
analysis of HIV-infected adults initiating ART in Johannesburg, South Africa</title>
        <description>Background:
Kaposi sarcoma (KS) is the most common AIDS-defining tumour in HIV-infected individuals in Africa. Kaposi sarcoma herpes virus (KSHV) infection precedes development of KS. KSHV co-infection may be associated with worse outcomes in HIV disease and elevated KSHV viral load may be an early marker for advanced HIV disease among untreated patients. We examined the prevalence of KSHV among adults initiating antiretroviral therapy (ART) and compared immunological, demographic and clinical factors between patients seropositive and seronegative for KSHV.
Results:
We analyzed cross-sectional data collected from 404 HIV-infected treatment-na&#239;ve adults initiating ART at the Themba Lethu Clinic, Johannesburg, South Africa between November 2008 and March 2009. Subjects were screened at ART initiation for antibodies to KSHV lytic K8.1 and latent Orf73 antigens. Seropositivity to KSHV was defined as positive to either lytic KSHV K8.1 or latent KSHV Orf73 antibodies. KSHV viremia was determined by quantitative PCR and CD3, 4 and 8 lymphocyte counts were determined with flow cytometry. Of the 404 participants, 193 (48%) tested positive for KSHV at ART initiation; with 76 (39%) reactive to lytic K8.1, 35 (18%) to latent Orf73 and 82 (42%) to both. One individual presented with clinical KS at ART initiation. The KSHV infected group was similar to those without KSHV in terms of age, race, gender, ethnicity, smoking and alcohol use. KSHV infected individuals presented with slightly higher median CD3 (817 vs. 726 cells/mm3) and CD4 (90 vs. 80 cells/mm3) counts than KSHV negative subjects. We found no associations between KSHV seropositivity and body mass index, tuberculosis status, WHO stage, HIV RNA levels, full blood count or liver function tests at initiation. Those with detectable KSHV viremia (n = 19), however, appeared to present with signs of more advanced HIV disease including anemia and WHO stage 3 or 4 defining conditions compared to those in whom the virus was undetectable.
Conclusions:
We demonstrate a high prevalence of KSHV among HIV-infected adults initiating ART in a large urban public-sector HIV clinic. KSHV viremia but not KSHV seropositivity may be associated with markers of advanced HIV disease.</description>
        <link>http://www.infectagentscancer.com/content/6/1/22</link>
                <dc:creator>Mhairi Maskew</dc:creator>
                <dc:creator>A Patrick MacPhail</dc:creator>
                <dc:creator>Denise Whitby</dc:creator>
                <dc:creator>Matthias Egger</dc:creator>
                <dc:creator>Carole Wallis</dc:creator>
                <dc:creator>Matthew Fox</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:22</dc:source>
        <dc:date>2011-11-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-22</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-22-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2011-11-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/21">
        <title>High-risk HPV infection after five years in a population-based cohort of Chilean women </title>
        <description>Background:
The need to review cervical cancer prevention strategies has been triggered by the availability of new prevention tools linked to human papillomavirus (HPV): vaccines and screening tests. To consider these innovations, information on HPV type distribution and natural history is necessary. This is a five-year follow-up study of gynecological high-risk (HR) HPV infection among a Chilean population-based cohort of women.FindingsA population-based random sample of 969 women from Santiago, Chile aged 17 years or older was enrolled in 2001 and revisited in 2006. At both visits they answered a survey on demographics and sexual history and provided a cervical sample for HPV DNA detection (GP5+/6+ primer-mediated PCR and Reverse line blot genotyping). Follow-up was completed by 576 (59.4%) women; 45 (4.6%) refused participation; most losses to follow-up were women who were unreachable, no longer eligible or had missing samples. HR-HPV prevalence increased by 43%. Incidence was highest in women &lt; 20 years of age (19.4%) and lowest in women &gt; 70 (0%); it was three times higher among women HR-HPV positive versus HPV negative at baseline (25.5% and 8.3%; OR 3.8, 95% CI 1.8-8.0). Type-specific persistence was 35.3%; it increased with age, from 0% in women &lt; 30 years of age to 100% in women &gt; 70. An enrollment Pap result ASCUS or worse was the only risk factor for being HR-HPV positive at both visits.
Conclusions:
HR-HPV prevalence increased in the study population. All HR-HPV infections in women &lt; 30 years old cleared, supporting the current recommendation of HR-HPV screening for women &gt; 30 years.</description>
        <link>http://www.infectagentscancer.com/content/6/1/21</link>
                <dc:creator>Catterina Ferreccio</dc:creator>
                <dc:creator>Vanessa Van De Wyngard</dc:creator>
                <dc:creator>Fabiola Olcay</dc:creator>
                <dc:creator>M. Angelica Dominguez</dc:creator>
                <dc:creator>Klaus Puschel</dc:creator>
                <dc:creator>Alejandro Corvalan</dc:creator>
                <dc:creator>Silvia Franceschi</dc:creator>
                <dc:creator>Peter Snijders</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:21</dc:source>
        <dc:date>2011-11-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-21</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-21-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2011-11-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/20">
        <title>Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women</title>
        <description>Background:
Infection with human papillomavirus (HPV) is associated with uterine cervical intraepithelial neoplasia (CIN) and invasive cancers (ICC). Approximately 80% of ICC cases are diagnosed in under-developed countries. Vaccine development relies on knowledge of HPV genotypes characteristic of LSIL, HSIL and cancer; however, these genotypes remain poorly characterized in many African countries. To contribute to the characterization of HPV genotypes in Northeastern Tanzania, we recruited 215 women from the Reproductive Health Clinic at Kilimanjaro Christian Medical Centre. Cervical scrapes and biopsies were obtained for cytology and HPV DNA detection.
Results:
79 out of 215 (36.7%) enrolled participants tested positive for HPV DNA, with a large proportion being multiple infections (74%). The prevalence of HPV infection increased with lesion grade (14% in controls, 67% in CIN1 cases and 88% in CIN2-3). Among ICC cases, 89% had detectable HPV. Overall, 31 HPV genotypes were detected; the three most common HPV genotypes among ICC were HPV16, 35 and 45. In addition to these genotypes, co-infection with HPV18, 31, 33, 52, 58, 68 and 82 was found in 91% of ICC. Among women with CIN2-3, HPV53, 58 and 84/83 were the most common. HPV35, 45, 53/58/59 were the most common among CIN1 cases.
Conclusions:
In women with no evidence of cytological abnormalities, the most prevalent genotypes were HPV58 with HPV16, 35, 52, 66 and 73 occurring equally. Although numerical constraints limit inference, findings that 91% of ICC harbor only a small number of HPV genotypes suggests that prevention efforts including vaccine development or adjuvant screening should focus on these genotypes.</description>
        <link>http://www.infectagentscancer.com/content/6/1/20</link>
                <dc:creator>Adriana Vidal</dc:creator>
                <dc:creator>Susan Murphy</dc:creator>
                <dc:creator>Brenda Hernandez</dc:creator>
                <dc:creator>Brandi Vasquez</dc:creator>
                <dc:creator>John Bartlett</dc:creator>
                <dc:creator>Olola Oneko</dc:creator>
                <dc:creator>Pendo Mlay</dc:creator>
                <dc:creator>Joseph Orube</dc:creator>
                <dc:creator>Francine Overcash</dc:creator>
                <dc:creator>Jennifer Smith</dc:creator>
                <dc:creator>Mike van der Kolk</dc:creator>
                <dc:creator>Cathrine Hoyo</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:20</dc:source>
        <dc:date>2011-11-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-20</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-20-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2011-11-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/19">
        <title>HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer </title>
        <description>Background:
HPV16 variants are associated with different risks for development of CIN3 and invasive cancer, although all are carcinogenic. The relationship of HPV 16 variants to cancer survival has not been studied.
Methods:
155 HPV16-positive cervical cancers were categorized according to European and non-European variant patterns by DNA sequencing of the E6 open reading frame. Clinico-pathologic parameters and clinical outcome were collected by chart review and death registry data.
Results:
Of the 155 women (mean age 44.7 years; median follow-up 26.7 months), 85.2% harbored European variants while 14.8% had non-European sequences. HPV16 variants differed by histologic cell type (p = 0.03) and stage (1 vs. 2+; p = 0.03). Overall, 107 women (68.0%) were alive with no evidence of cancer, 42 (27.1%) died from cervical cancer, 2 (1.3%) were alive with cervical cancer, and 4 (2.6%) died of other causes. Death due to cervical cancer was associated with European variant status (p &lt; 0.01). While 31% of women harboring tumors with European variants died from cervical cancer during follow-up, only 1 of 23 (4.4%) non-European cases died of cancer. The better survival for non-European cases was partly mediated by lower stage at diagnosis.
Conclusions:
Overall, invasive cervical cancers with non-European variants showed a less aggressive behavior than those with European variants. These findings should be replicated in a population with more non-European cases.</description>
        <link>http://www.infectagentscancer.com/content/6/1/19</link>
                <dc:creator>Rosemary Zuna</dc:creator>
                <dc:creator>Erin Tuller</dc:creator>
                <dc:creator>Nicolas Wentzensen</dc:creator>
                <dc:creator>Cara Mathews</dc:creator>
                <dc:creator>Richard Allen</dc:creator>
                <dc:creator>Rebecca Shanesmith</dc:creator>
                <dc:creator>S. Terence Dunn</dc:creator>
                <dc:creator>Michael Gold</dc:creator>
                <dc:creator>Sophia Wang</dc:creator>
                <dc:creator>Joan Walker</dc:creator>
                <dc:creator>Mark Schiffman</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:19</dc:source>
        <dc:date>2011-10-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-19</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-19-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2011-10-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/6/1/18">
        <title>Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein </title>
        <description>Background:
There is increasing evidence for the role of High Risk (HR) Human PapillomaVirus (HPV) in the pathogenesis of Oral Squamous Cell Carcinoma (OSCC). The E6 and E7 oncogenes from HR HPVs are responsible for the deregulation of p53 and pRB proteins involved in cell cycle and apoptotic pathways. In cell lines experiments, the HPV E7 protein seems to be able to enhance Hypoxia Inducible Factor-1 alpha (HIF-1&#945;) activity, normally involved in the response to hypoxia and able to enhance angiogenesis.
Results:
We studied tumor specimens from 62 OSCC; a higher prevalence of tumors in TNM stage II and also in pT2 class between OSCC infected positive HPV16 DNA than non-infected ones was observed. HIF-1&#945; positivity was detected throughout the analysed fields, not associated with areas of necrosis and also observed in cells immediately adjacent to blood vessels. A significant increase in mean values of the HIF-1&#945; labeling indexes was observed for pT1-T2, as well for stage I-II, in the infected positive HPV16 DNA tumors than non-infected ones. HIF-1&#945; and HPV16 E7 labeling indexes showed a significantly positive correlation which suggested a positive association between HPV16 E7 and HIF-1&#945; expression.
Conclusions:
In our specimens HIF-1&#945; immunoreactivity hints for an O2-independent regulatory mechanism in infected positive HPV16 DNA tumors, especially for pT1-T2 and stage I-II tumors, suggesting a very early involvement in the development of HPV-induced OSCC. HIF-1&#945; and HPV16 E7 labeling indexes suggest also a positive association between the two proteins in infected positive HPV16 DNA OSCC.</description>
        <link>http://www.infectagentscancer.com/content/6/1/18</link>
                <dc:creator>Vito Rodolico</dc:creator>
                <dc:creator>Walter Arancio</dc:creator>
                <dc:creator>Marco Amato</dc:creator>
                <dc:creator>Francesco Aragona</dc:creator>
                <dc:creator>Francesco Cappello</dc:creator>
                <dc:creator>Olga Di Fede</dc:creator>
                <dc:creator>Giuseppe Pannone</dc:creator>
                <dc:creator>Giuseppina Campisi</dc:creator>
                <dc:source>Infectious Agents and Cancer 2011, null:18</dc:source>
        <dc:date>2011-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-6-18</dc:identifier>
                                <prism:require>/content/figures/1750-9378-6-18-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2011-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

